KRMD

Repro Med Systems, Inc. [KRMD] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

KRMD Stock Summary

Top KRMD Correlated Resources

KRMD


Top 10 Correlated ETFs

KRMD


Top 10 Correlated Stocks

KRMD


In the News

05:25 05 Dec 2022 KRMD

KORU Medical Systems, Inc. (KRMD) Q3 2022 Earnings Call Transcript

KORU Medical Systems, Inc. (NASDAQ:KRMD ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Hannah Jeffrey - The Gilmartin Group Linda Tharby - President and CEO Tom Adams - Interim Chief Financial Officer Josh Bennett - VP of Strategy and Business Development Conference Call Participants Alexander Nowak - Craig-Hallum Capital Group Caitlin Cronin - Canaccord Genuity Joseph Downing - Piper Sandler Operator Greetings, and welcome to KORU Medical Systems Third Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

06:48 05 Dec 2022 KRMD

KORU Medical Systems Inc. (KRMD) Reports Q3 Loss, Tops Revenue Estimates

KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of 40% and 11.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

09:48 05 Dec 2022 KRMD

KORU Medical Systems, Inc. (KRMD) CEO Linda Tharby on Q2 2022 Results - Earnings Call Transcript

KORU Medical Systems, Inc. (NASDAQ:KRMD ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Gregory Chodaczek - Gilmartin Group Linda Tharby - President, CEO & Director Tom Adams - Interim CFO and VP, Financial Planning & Analysis Conference Call Participants Connor Stevenson - Craig-Hallum Gibran Ahmed - Canaccord Jason Bednar - Piper Sandler & Co. Operator Greetings, and welcome to KORU Medical Systems Second Quarter 2022 Earnings Conference Call. [Operator Instructions].

05:25 05 Dec 2022 KRMD

Repro Med Systems, Inc. (KRMD) CEO Linda Tharby on Q1 2022 Results - Earnings Call Transcript

Repro Med Systems, Inc. (NASDAQ:KRMD ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Greg Chodaczek - Managing Director Linda Tharby - President & CEO Karen Fisher - CFO, Treasurer & Corporate Secretary Conference Call Participants Chase Knickerbocker - Craig-Hallum Joseph Downing - Piper Sandler & Co. Operator Greetings, and welcome to KORU Medical Systems' First Quarter 2022 Earnings Conference Call. [Operator Instructions].

06:48 05 Dec 2022 KRMD

Repro Med Systems, Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates

Repro Med Systems, Inc. (KRMD) delivered earnings and revenue surprises of 16.67% and 4.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

09:29 05 Dec 2022 KRMD

Repro Med Systems, Inc. (KRMD) CEO Linda Tharby on Q4 2021 Results - Earnings Call Transcript

Repro Med Systems, Inc. (KRMD) CEO Linda Tharby on Q4 2021 Results - Earnings Call Transcript

07:06 05 Dec 2022 KRMD

Repro Med Systems, Inc. (KRMD) Reports Q4 Loss, Tops Revenue Estimates

Repro Med Systems, Inc. (KRMD) delivered earnings and revenue surprises of 33.33% and 5.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

04:09 05 Dec 2022 KRMD

Analysts Estimate Repro Med Systems, Inc. (KRMD) to Report a Decline in Earnings: What to Look Out for

Repro Med Systems, Inc. (KRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

12:30 05 Dec 2022 KRMD

CORRECTING and REPLACING KORU Medical Systems to Report Fourth Quarter and Full Year 2021 Financial Results on March 2, 2022

CHESTER, N.Y.--(BUSINESS WIRE)--First paragraph, first sentence of release dated February 16, 2022, should read: Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced that the Company will report fourth quarter and full year 2021 financial results on Wednesday, March 2, 2022. [instead of Repro Med Systems, Inc. dba KO

09:01 05 Dec 2022 KRMD

Repro Med Systems, Inc. (KRMD) CEO Linda Tharby on Q3 2021 Results - Earnings Call Transcript

Repro Med Systems, Inc. (KRMD) CEO Linda Tharby on Q3 2021 Results - Earnings Call Transcript

KRMD Financial details

Company Rating
Buy
Market Cap
141.05M
Income
-7.75M
Revenue
27.04M
Book val./share
0.72
Cash/share
0.37
Dividend
-
Dividend %
-
Employees
77
Optionable
No
Shortable
Yes
Earnings
28 Feb 2023
P/E
-23.78
Forward P/E
-16.39
PEG
-0.49
P/S
5.19
P/B
4.32
P/C
8.42
P/FCF
-11.2
Quick Ratio
3.6
Current Ratio
4.98
Debt / Equity
0.12
LT Debt / Equity
0.12
-
-
EPS (TTM)
-0.18
EPS next Y
-0.19
EPS next Q
0.02
EPS this Y
233.33%
EPS next Y
4.52%
EPS next 5Y
4.52%
EPS last 5Y
NAN%
Revenue last 5Y
8.75%
Revenue Q/Q
18.54%
EPS Q/Q
-61.43%
-
-
-
-
SMA20
25%
SMA50
19.34%
SMA100
16%
Inst Own
36.36%
Inst Trans
0.36%
ROA
-18%
ROE
-23%
ROC
-0.28%
Gross Margin
56%
Oper. Margin
-38%
Profit Margin
-29%
Payout
-
Shs Outstand
45.03M
Shs Float
25.09M
-
-
-
-
Target Price
3
52W Range
1.82-3.64
52W High
+3.83%
52W Low
+211.5%
RSI
72.26
Rel Volume
1.57
Avg Volume
33.93K
Volume
53.19K
Perf Week
10.46%
Perf Month
31.99%
Perf Quarter
59.74%
Perf Half Y
55.75%
-
-
-
-
Beta
0.345665
-
-
Volatility
0.1%, 0.29%
Prev Close
1.8%
Price
3.115
Change
7.04%

KRMD Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-02-282018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
0.320.460.60.580.53
Net income per share
-0.010.020.01-0.03-0.1
Operating cash flow per share
-0.010.040.01-0.02-0.1
Free cash flow per share
-0.020.030-0.04-0.11
Cash per share
0.090.140.150.650.57
Book value per share
0.180.240.290.860.82
Tangible book value per share
0.170.220.270.830.8
Share holders equity per share
0.180.240.290.860.82
Interest debt per share
00000
Market cap
16.08M58.34M240.42M169.4M122.5M
Enterprise value
12.76M54.6M234.7M142.22M97.36M
P/E ratio
-30.0564.07426.02-143.99-26.85
Price to sales ratio
1.313.3610.387.015.22
POCF ratio
-48.4839.43749.87-227.89-28.36
PFCF ratio
-21.5358.42-2.29K-93.88-26.26
P/B Ratio
2.416.5121.44.693.36
PTB ratio
2.416.5121.44.693.36
EV to sales
1.043.1510.135.884.14
Enterprise value over EBITDA
-26.9236.74226.4-183.36-42.37
EV to operating cash flow
-38.4936.9732-191.34-22.54
EV to free cash flow
-17.0954.68-2.24K-78.82-20.87
Earnings yield
-0.030.020-0.01-0.04
Free cash flow yield
-0.050.020-0.01-0.04
Debt to equity
00000
Debt to assets
0.180.150.190.10.12
Net debt to EBITDA
6.99-2.52-5.5335.0310.94
Current ratio
4.885.74.9410.247.79
Interest coverage
-390.380000
Income quality
0.621.620.570.630.95
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00.520.420.50
Research and developement to revenue
0.020.010.030.050.11
Intangibles to total assets
0.050.060.060.020.02
Capex to operating cash flow
1.25-0.33-1.331.430.08
Capex to revenue
-0.03-0.03-0.02-0.04-0.01
Capex to depreciation
-1.38-1.56-1.25-2.54-0.75
Stock based compensation to revenue
0.020.020.050.070.12
Graham number
0.240.360.310.741.38
ROIC
-0.110.130.05-0.03-0.19
Return on tangible assets
-0.070.090.04-0.03-0.11
Graham Net
0.110.150.180.690.6
Working capital
5.39M7.45M9.48M33.86M32.53M
Tangible asset value
6.25M8.33M10.43M34.93M35.69M
Net current asset value
5.29M7.45M9.24M33.76M32.53M
Invested capital
000.0100.01
Average receivables
2.12M2M2.9M2.57M3.44M
Average payables
698.67K539.21K598.79K624.92K926.23K
Average inventory
4.09M4.47M4.61M6.83M6.47M
Days sales outstanding
49.7229.9950.9738.8466.99
Days payables outstanding
59.6825.325.1624.6846.09
Days of inventory on hand
104.59117.36104.92269.78229.29
Receivables turnover
7.3412.177.169.45.45
Payables turnover
6.1214.4314.5114.797.92
Inventory turnover
3.493.113.481.351.59
ROE
-0.080.10.05-0.03-0.13
Capex per share
-0.01-0.01-0.01-0.03-0.01

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-09-302021-12-312022-03-312022-06-30 2022-09-30
Revenue per share
0.140.150.140.150.17
Net income per share
-0.02-0.02-0.06-0.07-0.03
Operating cash flow per share
-0.02-0.02-0.04-0.06-0.09
Free cash flow per share
-0.02-0.02-0.06-0.09-0.12
Cash per share
0.590.570.510.410.37
Book value per share
0.830.820.780.730.72
Tangible book value per share
0.830.80.780.710.7
Share holders equity per share
0.830.820.780.730.72
Interest debt per share
0.0200.10.10.11
Market cap
126.32M133.71M127.75M113.65M100.44M
Enterprise value
100.89M108.57M109.74M99.93M89.05M
P/E ratio
-28.87-31.29-12.59-9.73-20.49
Price to sales ratio
20.9120.620.4617.3612.94
POCF ratio
-152.89-186.46-72.91-39.56-25.97
PFCF ratio
-129.22-181.74-51-28.07-19.19
P/B Ratio
3.433.663.673.483.09
PTB ratio
3.433.663.673.483.09
EV to sales
16.716.7317.5715.2611.48
Enterprise value over EBITDA
-82.9747.78-36.25-28.53-119.17
EV to operating cash flow
-122.11-151.39-62.63-34.78-23.02
EV to free cash flow
-103.2-147.56-43.81-24.68-17.02
Earnings yield
-0.01-0.01-0.02-0.03-0.01
Free cash flow yield
-0.01-0.01-0.02-0.04-0.05
Debt to equity
000.110.130.12
Debt to assets
0.110.120.20.230.24
Net debt to EBITDA
20.91-11.075.953.9215.23
Current ratio
8.267.797.25.44.98
Interest coverage
002.14K-1.01K-36.01
Income quality
0.760.670.690.983.16
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.130.150.180.20.11
Intangibles to total assets
00.0200.020.02
Capex to operating cash flow
0.180.030.430.410.35
Capex to revenue
-0.030-0.12-0.18-0.18
Capex to depreciation
-1.31-0.16-6.89-9.34-4.99
Stock based compensation to revenue
0.10.110.130.110.21
Graham number
0.680.6611.030.66
ROIC
-0.04-0.06-0.08-0.1-0.04
Return on tangible assets
-0.03-0.03-0.06-0.07-0.03
Graham Net
0.620.60.440.340.31
Working capital
33.1M32.53M29.22M25.24M24.57M
Tangible asset value
035.69M031.83M31.69M
Net current asset value
33.1M32.53M25.3M21.13M20.57M
Invested capital
0.020.010.130.140.16
Average receivables
3.94M4.54M4.3M4.77M5.26M
Average payables
1.89M1.81M1.83M2.39M1.88M
Average inventory
6.87M6.44M6.39M6.77M6.83M
Days sales outstanding
46.5359.7855.1465.5166.76
Days payables outstanding
4941.5543.5267.2135.75
Days of inventory on hand
246.43206.71206.56190.42180.21
Receivables turnover
1.931.511.631.371.35
Payables turnover
1.842.172.071.342.52
Inventory turnover
0.370.440.440.470.5
ROE
-0.03-0.03-0.07-0.09-0.04
Capex per share
00-0.02-0.03-0.03

KRMD Frequently Asked Questions

What is Repro Med Systems, Inc. stock symbol ?

Repro Med Systems, Inc. is a US stock , located in Chester new york of New york and trading under the symbol KRMD

Is Repro Med Systems, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $3. The lowest prediction is $3 and the highest is $3

What is KRMD stock prediction ?

What is Repro Med Systems, Inc. stock quote today ?

Repro Med Systems, Inc. stock price is $3.115 today.

Is Repro Med Systems, Inc. stock public?

Yes, Repro Med Systems, Inc. is a publicly traded company.

Something similar

Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap